WP
VVOS icon

WMS Partners’s Vivos Therapeutics VVOS Stock Holding History

WMS Partners’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-487
Closed -$49K – 294
2021
Q3 		$49K Sell
487
-180
-27% -$18.9K 0.01% 272
2021
Q2 		$153K Buy
+667
New +$109K 0.02% 252

Other funds holding VVOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

WMS Partners's VVOS Position: Q4 2021 in Review

WMS Partners sold out of Vivos Therapeutics (VVOS) in Q4 2021, closing a stake of 487 shares — an estimated $49K sold.

WMS Partners first reported a position in VVOS in Q2 2021 and held it in 2 quarters. The position peaked at $153K in Q2 2021. 29 funds tracked by Wall St. Rank hold VVOS as of Q4 2021.

  • WMS Partners reported no remaining Vivos Therapeutics position as of Q4 2021 after selling out during the quarter.
  • WMS Partners sold 487 Vivos Therapeutics shares in Q4 2021, an estimated $49K.
  • WMS Partners first reported a position in Vivos Therapeutics in Q2 2021 and held it in 2 quarters.
  • WMS Partners's Vivos Therapeutics position peaked at $153K in Q2 2021.
  • 29 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q4 2021.

Based on WMS Partners's 13F filing for Q4 2021, filed 14 Feb 2022.